Back to Freepaper Session

Management of corneal angiogenesis with the use of sub conjuctival injection of Bevacizumab 2.5mg/ 0.1ml

Session Details

Session Title: Cornea Medical

Session Date/Time: Monday 07/10/2013 | 08:00-10:00

Paper Time: 08:50

Venue: Elicium 1 (First Floor)

First Author: : S.Nankani INDIA

Co Author(s): :                  

Abstract Details

Purpose:

To determine the anti angiogenetic effect of sub conjuctival application of Bevacizumab for inhibition and treatment of Corneal angiogenesis ( both non established vascularisation and established vascularisation)

Setting:

Krishna Eye Centre, Mumbai, India

Methods:

30 eyes of 30 patients with Corneal angiogenesis were divided into 2 groups. Group A: Corneal Neovascularisation of single quadrant. Group B: established vascularisation and neovascularisation of 2 or more quadrants. All eyes were injected with 2.5mg/0.1ml of Bevacizumab subconjuctivally, 2 mm away from the limbus. All patients were followed up for examination and photographed post injection at 1 week, 1 month, 3 months and 6 months.

Results:

All 30 eyes with neovascularisation showed regression of vasculature which was obvious at the end of 1 week and lasted for 3 months. Eyes with established vasculature failed to show any regression at the end of 1 week, 1 month or 3 months. at the end of 3 months, 8 eyes showed regrowth of vasculature and responded in respect to how many quadrants were involved to the injection

Conclusions:

Data presented in this study demonstrates the effectiveness of subconjuctival application of Bevacizumab for inhibition and treatment of non established neovascularisation of the cornea, though 25% of the eyes required reinjection between 3 to 6 months

Financial Interest:

NONE